Preclinical Phase

Lantern Pharma Inc (NASDAQ: LTRN) announced preclinical data of its drug candidate LP-184, showing its potential to inhibit tumor growth and improve survival in animals models of glioblastoma (GBM). LP-184 treatment induced tumor regression evidenced by greater than 106% tumor...

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has announced the data publication for its preclinical compound, Amilo-5MER, in the Journal of Autoimmunity. Amilo-5MER is a five amino acid in a specific sequence originally isolated from synovial fluid of rheumatoid arthritis patients....

Plus Therapeutics Inc (NASDAQ: PSTV) has presented preclinical data of its lead investigational drug, Rhenium-186 Nanoliposome (186RNL), for leptomeningeal metastases (LM). The data were presented at the Third Annual Conference on Brain Metastases hosted by the Society for Neuro-...

Werewolf Therapeutics Inc (NASDAQ: HOWL) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK) to evaluate WTX-124 in combination with Keytruda (pembrolizumab). WTX-124 is a systemically delivered, conditionally activated...

Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) has announced additional results from preclinical studies of its lead clinical compound, LB-100, a protein phosphatase 2A (PP2A) inhibitor. Data showed to reduce behavioral sensitization underlying addiction to methamphetamine. ...

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has added two assets to expand its rare autoimmune and kidney-related disease pipeline. The first program, AUR200, was acquired from privately-held Thunderbolt Pharma Inc.  AUR200 is a recombinant Fc fusion protein designed to...

Mustang Bio Inc (NASDAQ: MBIO) executed an exclusive license agreement with Mayo Clinic for a new approach to administering chimeric antigen receptor engineered T cell (CAR T) therapies and potentially be used as an off-the-shelf therapy. The technology uses a two-step...

Affimed NV (NASDAQ: AFMD) has announced the publication of in vitro and in vivo research of its lead innate cell engager (ICE), AFM13 (CD16A/CD30), combined with healthy donor-derived Natural killer (NK) cells, in Clinical Cancer Research. The preclinical data demonstrated that...

Can-Fite BioPharma (NYSE: CANF) has initiated a series of preclinical studies required by regulators to support potential marketing registration filings for its drug candidates Piclidenoson and Namodenoson in the U.S. and Europe. As part of marketing applications in the U.S....